Search our team at AdventHealth Research Institute
-
NCT05650879
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients with HER2 Mutant Non-Small Cell Lung Cancer
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to test the safety and early signs of efficacy of an experimental drug called ELVN-002 for the treatment of solid tumors carrying HER2 genetic alterations, in particular...
-
Phase II Trial of Trilaciclib added to Chemotherapy plus Pembrolizumab in the First-line Treatment of patients with Advanced Non-Small Cell Lung Cancer.
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer Research -
NCT05671510
PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchThe main purpose of the study is to determine whether the study drug, ONC-392, is safe and well tolerated, and whether it is effective in treating lung cancer, in comparison with a standard of care...
-
NCT05261399
We are doing this research study to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC). Investigational means that the drug is not approved by any health authority, except for use in research studies like this. Osimertinib is approved by health authorities for treatment of NSCLC. Osimertinib is known to work well initially, but resistance often occurs after several months of treatment.
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaWe are doing this research study to learn more about an investigational drug called savolitinib in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC). Investigational...
-
NCT05364073
FURMO-002: A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating EGFR or HER2 Mutations, Including Exon 20 Insertion Mutations
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchThe purpose of this study is to learn about how the study drug, furmonertinib, works in patients with NSCLC who have a mutation in the EGFR or HER2 gene and how it may help them. For patients with...
-
NCT05498428
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer
This study is currently enrolling.Research Area: Cancer ResearchResearch Location: Orlando, FloridaThe investigational anti-cancer drugs being studied are called amivantamab (JNJ-61186372) and lazertinib (JNJ-73841937). They are being developed for the treatment of locally advanced or metastatic (i...
-
PD-L1 expression in lung adenocarcinomas with different subtypes of KRAS mutations and its clinical significance
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchThe purpose of this study is to evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation which may impact outcomes (survivals and/or pattern of metastasis) of lung...
-
NCT06008093
D419ML00003: A Phase IIIb, Randomized, Multicenter, Open-label study, to assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination with Platinum Based Chemotherapy for First Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients who have Mutations or Co mutations in STK11, KEAP1, or KRAS (TRITON)
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaTo assess the efficacy of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in terms of OS, in participants with non-squamous histology who have metastatic...
-
NCT05639751
PRT3789-01: A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purpose of this research study is to test the safety of PRT3789 at different dose levels to find out what effects, good and/or bad, PRT3789 has on you and your type of cancer. The information...
-
NCT05211895
D9075C00001: A Phase 3, Randomized, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab and Domvanalimab (AB154) as Sequential Therapy in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive, Platinum-based Concurrent Chemoradiation Therapy (PACIFIC 8)
This study is currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis study is being carried out in stage III NSCLC which cannot be removed by surgery. In this study, we will identify the effectiveness and safety of a possible treatment combination – durvalumab...
-
NCT02367781
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer
This study is not currently enrolling.Associated Conditions: Lung CancerResearch Area: Cancer Research[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you...